PapersPMID:37822243
The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“The ORRs and DCRs did not differ significantly between the fucoidan and placebo groups (P =.973 and P =.543, respectively, Table 1).”
- Study
- RCT
- Participants
- 87
- Dose studied
- 4 g twice daily orally for 3 months
- Population
- Adults with locally advanced rectal cancer; all patients in both arms received neoadjuvant concurrent chemoradiotherapy with mFOLFOX6 and radiotherapy
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant concurrent chemoradiotherapy (mFOLFOX6 plus radiotherapy) before surgery; low-molecular-weight fucoidan from Sargassum hemiphyllum versus cellulose placebo
- Participants
- 87
- Comparator
- placebo
- Duration
- 91 days
- Endpoints measured
- 52